Gerald Ray, DO
Family Medicine · Mansfield, TXNPI 1720067119
Payments from drug & device makers
Across 267 payments — averaging $15.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$594
- Lilly USA, LLC$515
- Novo Nordisk$481
- AstraZeneca$438
- GSK$359
- Pfizer$249
- plus $2K from 30 others
What the payments were for
- Food & beverage$4,224100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 48 | $594 |
| Lilly USA, LLC | 30 | $515 |
| Novo Nordisk | 32 | $481 |
| AstraZeneca | 29 | $438 |
| GSK | 22 | $359 |
| Pfizer | 13 | $249 |
| Biohaven Pharmaceutical Holding Company Ltd. | 13 | $247 |
| Exact Sciences | 8 | $172 |
| Antares Pharma, Inc. | 7 | $130 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $120 |
| Echosens North America, Inc. | 3 | $87 |
| Astellas Pharma US Inc | 5 | $71 |
| Merck | 5 | $69 |
| Novartis | 4 | $63 |
| Abbott | 3 | $55 |
| IBSA Pharma Inc. | 3 | $49 |
| Johnson & Johnson | 3 | $47 |
| Bayer | 3 | $47 |
| Teva Pharmaceuticals USA, Inc. | 3 | $45 |
| Idorsia Pharmaceuticals US Inc | 3 | $41 |
| Boehringer Ingelheim | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $38 |
| Amarin Pharma, Inc. | 3 | $35 |
| Amgen | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $28 |
| Avion Pharmaceuticals | 2 | $26 |
| Supernus Pharmaceuticals, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Vertical Pharmaceuticals, LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $16 |
| Phadia US Inc. | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Upsher-smith Laboratories LLC | 1 | $13 |
| Therapeuticsmd, Inc. | 1 | $12 |
How this compares
$4,236 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 64 | $90,549 |
| OzempicSemaglutide | 33 | $43,694 |
| EliquisApixaban | 22 | $23,304 |
| ProgesteroneProgesterone, Micronized | 226 | $18,010 |
| MyrbetriqMirabegron | 16 | $15,238 |
| Testosterone Cypionate | 113 | $7,316 |
| Liothyronine Sodium | 130 | $6,959 |
| Estradiol | 216 | $5,096 |
| SynthroidLevothyroxine Sodium | 19 | $2,336 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 33 | $2,037 |
| Levothyroxine Sodium | 162 | $1,917 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $1,151 |
| Omeprazole | 51 | $1,148 |
| Losartan Potassium | 77 | $795 |
| Ventolin HfaAlbuterol Sulfate | 12 | $639 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $515 | $90,54964 claims |
| Novo NordiskOzempic | $481 | $43,69433 claims |
| PfizerEliquis | $249 | $23,30422 claims |
| Astellas Pharma US IncMyrbetriq | $71 | $15,23816 claims |
| AbbVieSynthroid | $594 | $2,33619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Mansfield
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.